Power doppler harmonic imaging: a feasibility study of a new technique for the assessment of myocardial perfusion.
Power doppler harmonic imaging: a feasibility study of a new technique for the assessment of myocardial perfusion.
复制标题
功率多普勒谐波成像：评估心肌灌注新技术的可行性研究。
DOI：
10.1067/mhj.2000.101488
复制
发表时间：
2000
影响因子：
4.8
通讯作者：
Lahiri,A
中科院分区：
文献类型：
--
作者：
Senior,R;Kaul,S;Soman,P;Lahiri,A
背景：本研究的目的是评价一种新的超声造影剂用于静脉注射微泡评价心肌血流灌注的可行性。方法与结果15例确诊为冠状动脉疾病的患者，在99mTc-Sestamibi单光子发射计算机断层扫描(SPECT)检查中发现静息血流灌注异常，静注新一代超声造影剂Sonovue(意大利米兰)2~3mLSonovue，同时进行静息PDHI检查。通过2名PDHI和SPECT盲人观察者使用5节段模型来确定心肌灌注的存在或消失。在总共75个可能的心肌节段中，7个(9%)因PDHI上明显的伪影而未被分析。SPECT显示剩余68个节段中有40个节段存在灌注缺陷，而PDHI显示39个节段存在灌注缺陷。两种成像方式对缺陷存在的符合率(93%)和位置(前间隔96%，后下93%，心尖部87%)具有很高的符合率。结论经静脉注射新的第二代超声造影剂后，PDHI是检测冠心病患者静息心肌灌注缺陷的一种可行技术。
Background The aim of the study was to assess the feasibility of a new technique, power Doppler harmonic imaging (PDHI), for assessing myocardial perfusion through a venous injection of microbubbles, with the use of a new ultrasound contrast agent. Methods and Results Fifteen patients with known coronary artery disease and a resting perfusion abnormality on Tc-99m sestamibi single-photon emission computed tomography (SPECT) underwent PDHI at rest during intravenous injections of 2 to 3 mL of Sonovue (Bracco SpA, Milan, Italy), a new second-generation ultrasound contrast agent. Myocardial perfusion was determined to be present or absent by use of a 5-segment model by 2 blinded observers for both PDHI and SPECT. Of a total of 75 possible myocardial segments, 7 (9%) were not analyzed because of obvious artifacts on PDHI. SPECT showed perfusion defects in 40 of the remaining 68 segments, whereas PDHI showed 39 defects. There was high concordance between the 2 imaging modalities for the presence (93%) as well as the location (96% for the anteroseptal region, 93% for the inferoposterior region, and 87% for the apical region) of the defects. Conclusions These preliminary results suggest that PDHI is a feasible technique for the detection of resting myocardial perfusion defects in patients with coronary artery disease after a venous injection of a new second-generation ultrasound contrast agent.